S&P Futures
6,010.00 +23.00 (+0.38%) Dow Futures
44,604.00 +209.00 (+0.47%) Nasdaq Futures
20,945.25 +95.50 (+0.46%) Russell 2000 Futures
2,440.40 +26.80 (+1.11%) Crude Oil
71.28 +0.04 (+0.06%) Gold
2,713.90 +1.70 (+0.06%)
ESSA Pharma Inc. (EPIX)
After hours:
| Previous Close | 1.7600 |
| Open | 1.7400 |
| Bid | 1.8000 x 300 |
| Ask | 1.8700 x 200 |
| Day's Range | 1.7325 - 1.8540 |
| 52 Week Range | 1.4000 - 11.6700 |
| Volume | |
| Avg. Volume | 825,040 |
| Market Cap | 81.231M |
| Beta (5Y Monthly) | 1.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6200 |
| Earnings Date | Dec 10, 2024 - Dec 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.20 |
Simply Wall St.ESSA Pharma And 2 Other US Penny Stocks To Watch
As the U.S. stock market reaches record highs amid an election-fueled rally, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, often seen as a relic of past trading days, still hold significant potential for growth and value discovery in today's market landscape. These smaller or newer companies can offer a mix of affordability and upside potential when backed by strong financials, presenting an underappreciated avenue for investors...
- Investing.com
ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trials
ESSA Pharma (NASDAQ:EPIX), a biotechnology company focused on developing treatments for metastatic castration-resistant prostate cancer, saw its stock downgraded by major brokerages Oppenheimer and Piper Sandler after the company said it was halting development of its lead drug candidate, masofaniten. This decision followed a futility analysis during a Phase II clinical trial, where masofaniten, combined with the existing anti-cancer drug enzalutamide, was being evaluated against enzalutamide alone.
